enGene (NASDAQ:ENGN) Releases Quarterly Earnings Results, Meets Estimates

enGene (NASDAQ:ENGN) announced its earnings results on Tuesday. The company reported ($0.47) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.47), FiscalAI reports.

enGene Stock Performance

enGene stock opened at $1.82 on Tuesday. The firm has a market capitalization of $121.92 million, a PE ratio of -0.84 and a beta of -0.28. The firm’s 50 day simple moving average is $1.82 and its 200 day simple moving average is $4.11. The company has a current ratio of 12.57, a quick ratio of 12.57 and a debt-to-equity ratio of 0.10. enGene has a 1-year low of $1.40 and a 1-year high of $12.25.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of enGene in a research note on Wednesday, August 12th. Wall Street Zen raised shares of enGene from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. HC Wainwright dropped their target price on shares of enGene from $6.00 to $4.00 and set a “buy” rating for the company in a research report on Tuesday, June 16th. Morgan Stanley lowered shares of enGene from an “equal weight” rating to an “underweight” rating and set a $3.00 price objective on the stock. in a research note on Thursday, June 18th. Finally, UBS Group dropped their target price on shares of enGene from $9.00 to $2.00 and set a “neutral” rating on the stock in a research report on Thursday, May 14th. Four analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, enGene currently has an average rating of “Hold” and a consensus target price of $11.05.

Institutional Trading of enGene

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. MPM Bioimpact LLC raised its position in enGene by 247.1% during the 4th quarter. MPM Bioimpact LLC now owns 1,840,898 shares of the company’s stock worth $16,623,000 after buying an additional 1,310,599 shares during the last quarter. Braidwell LP lifted its holdings in shares of enGene by 38.2% in the 4th quarter. Braidwell LP now owns 3,131,319 shares of the company’s stock valued at $28,276,000 after purchasing an additional 865,000 shares during the last quarter. Siren L.L.C. acquired a new position in shares of enGene during the fourth quarter worth about $30,126,000. Janus Henderson Group PLC acquired a new stake in enGene in the 4th quarter valued at about $17,110,000. Finally, Vestal Point Capital LP increased its stake in enGene by 185.1% in the fourth quarter. Vestal Point Capital LP now owns 1,055,000 shares of the company’s stock valued at $9,527,000 after purchasing an additional 685,000 shares during the last quarter. Hedge funds and other institutional investors own 64.16% of the company’s stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.